Ew Healthcare Partners Fund 2, Purchases 5,000 Shares of TELA Bio, Inc. (NASDAQ:TELA) Stock

TELA Bio, Inc. (NASDAQ:TELAGet Rating) insider Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock in a transaction on Monday, May 23rd. The stock was bought at an average price of $8.53 per share, with a total value of $42,650.00. Following the completion of the acquisition, the insider now directly owns 3,435,709 shares of the company’s stock, valued at approximately $29,306,597.77. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Ew Healthcare Partners Fund 2, also recently made the following trade(s):

  • On Friday, May 20th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The stock was bought at an average price of $8.79 per share, with a total value of $43,950.00.
  • On Wednesday, May 18th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The stock was bought at an average price of $8.96 per share, with a total value of $44,800.00.
  • On Monday, May 16th, Ew Healthcare Partners Fund 2, bought 5,000 shares of TELA Bio stock. The stock was acquired at an average price of $8.61 per share, for a total transaction of $43,050.00.
  • On Friday, May 13th, Ew Healthcare Partners Fund 2, bought 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $8.48 per share, with a total value of $42,400.00.
  • On Wednesday, May 11th, Ew Healthcare Partners Fund 2, bought 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $8.82 per share, with a total value of $44,100.00.
  • On Monday, May 9th, Ew Healthcare Partners Fund 2, bought 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $9.38 per share, with a total value of $46,900.00.
  • On Friday, May 6th, Ew Healthcare Partners Fund 2, bought 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $9.55 per share, with a total value of $47,750.00.
  • On Wednesday, May 4th, Ew Healthcare Partners Fund 2, bought 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $9.53 per share, with a total value of $47,650.00.
  • On Monday, May 2nd, Ew Healthcare Partners Fund 2, bought 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $9.32 per share, with a total value of $46,600.00.
  • On Friday, April 29th, Ew Healthcare Partners Fund 2, bought 5,000 shares of TELA Bio stock. The shares were acquired at an average cost of $9.17 per share, with a total value of $45,850.00.

NASDAQ TELA traded down $1.63 during trading hours on Tuesday, hitting $6.71. The company had a trading volume of 111,144 shares, compared to its average volume of 34,812. TELA Bio, Inc. has a 52 week low of $6.32 and a 52 week high of $16.53. The firm has a 50 day simple moving average of $10.14 and a 200 day simple moving average of $11.55. The company has a debt-to-equity ratio of 3.15, a quick ratio of 3.26 and a current ratio of 4.10. The firm has a market capitalization of $97.68 million, a price-to-earnings ratio of -2.71 and a beta of 1.57.

TELA Bio (NASDAQ:TELAGet Rating) last issued its earnings results on Tuesday, May 10th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.25). TELA Bio had a negative return on equity of 155.13% and a negative net margin of 113.15%. During the same period in the prior year, the company posted ($0.56) earnings per share. On average, research analysts forecast that TELA Bio, Inc. will post -2.47 earnings per share for the current year.

Several brokerages recently weighed in on TELA. JMP Securities reissued a “buy” rating and issued a $22.00 price objective on shares of TELA Bio in a report on Tuesday, March 22nd. Zacks Investment Research raised TELA Bio from a “sell” rating to a “hold” rating in a report on Tuesday.

Hedge funds and other institutional investors have recently modified their holdings of the business. Morgan Stanley boosted its stake in TELA Bio by 3,256.9% in the 2nd quarter. Morgan Stanley now owns 6,781 shares of the company’s stock worth $109,000 after purchasing an additional 6,579 shares during the period. Bank of America Corp DE boosted its position in shares of TELA Bio by 16.6% during the 2nd quarter. Bank of America Corp DE now owns 7,682 shares of the company’s stock valued at $124,000 after acquiring an additional 1,093 shares during the last quarter. Susquehanna International Group LLP bought a new stake in shares of TELA Bio during the 4th quarter valued at about $254,000. BlackRock Inc. boosted its position in shares of TELA Bio by 4.1% during the 4th quarter. BlackRock Inc. now owns 22,392 shares of the company’s stock valued at $287,000 after acquiring an additional 886 shares during the last quarter. Finally, State Street Corp boosted its position in shares of TELA Bio by 9.1% during the 1st quarter. State Street Corp now owns 26,065 shares of the company’s stock valued at $303,000 after acquiring an additional 2,167 shares during the last quarter.

TELA Bio Company Profile (Get Rating)

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

Further Reading

Insider Buying and Selling by Quarter for TELA Bio (NASDAQ:TELA)

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.